The Board of Directors of Active Biotech AB (publ) has today issued a
notification of the Annual General Meeting, which is to take place at
5 p.m. on Thursday, May 7, 2009, at the Company's premises at
Scheelevägen 22 in Lund, Sweden.
Please see the attached notification, which is being published on
April 9 in Svenska Dagbladet and Post- och Inrikes Tidningar.
Lund, April 6, 2009
ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology
company with R&D focus on autoimmune/inflammatory diseases and
cancer. Projects in pivotal phases are laquinimod, an orally
administered small molecule with unique immunomodulatory properties
for the treatment of multiple sclerosis, and ANYARA for use in cancer
targeted therapy, primarily renal cancer. Further key projects in
clinical development comprise the three orally administered compounds
TASQ for prostate cancer, 57-57 for SLE and RhuDexTM for RA.
Active Biotech AB
P.O. Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech is obligated to publish the information contained in
this press release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication on
April 6, 2009, at 8:30 a.m.
